The survival from bronchogenic carcinoma is highly dependent upon stage at the time of treatment. This is particularly true for squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, but holds true for small cell carcinoma as well. The problem presented to the medical profession has been to find a practical means of detecting lung cancer while it is still at an early stage. Three studies in progress have indicated that a larger proportion of the patients may be found to have early stage lung cancer when screened with a combination of chest X-rays and sputum cytology. However, the detection of these early stage cases has not yet been translated into an improvement in the overall mortality rate from lung cancer.
PROBLEM
The incidence of lung cancer has continued to climb dramatically throughout the last fifty years. In 1930, the incidence of lung cancer was approximately five per 100,000 men. In 1970 it was approximately 14 times as high with an incidence of 70 per 100,000. The American Cancer Society estimates that 122,000 people in this country will get lung cancer in 1981 and that 105,000 of them will die of this disease. Approximately one American will die of lung cancer every five minutes. The overall five-year survival from lung cancer in men is 8 percent. In large part, this is due to the fact that only 17 percent of lung cancers present clinically as localized disease. The remainder of the patients have either regional or distant metastases at the time of discovery [1] .
The survival from bronchogenic carcinoma is highly dependent upon stage at the time of treatment. The American Joint Commission has devised a TNM system for bronchogenic carcinoma [2] . T stands for tumor, N for lymph node metastases, and M for distant metastases. In Stage I disease (local disease) the five-year survival from squamous cell carcinoma is approximately 38 percent, large cell carcinoma 31 percent, and adenocarcinoma 32 percent. In Stage II (regional) disease the five-year survival for squamous cell carcinoma drops to 16 percent, for large cell undifferentiated to 7 percent, and for adenocarcinoma to 8 percent. For Stage III disease (tumor which has invaded from the lung into the thoracic contents, or which has metastasized to the mediastinum or to distant viscera) the five-year survival for squamous cell carcinoma is 10 percent, for large cell undifferentiated carcinoma 5 percent, and for adenocarcinoma 3 percent [2] .
Even small cell carcinoma can be broken into groups on the basis of the apparent In the pre-carcinoma phase, the presence of a lesion can be detected only by finding dysplastic cells in sputum. This has been done on relatively few occasions. Saccomanno [7] [5] . There are problems related to the finding of tumors in this early stage of their clinical course [8] . Careful localization with fiberoptic bronchoscopy is required [9, 10] . Extension of even very early squamous cell carcinoma to proximal or lobar bronchial margins, the presence of multifocal disease appearing either synchronously or subsequently, and the extent of underlying pulmonary disease in this group of patients create problems for the surgeon attempting to treat such lesions conservatively [11] . Nevertheless the results of treatment in this stage are among the best achieved for bronchogenic carcinoma. In 89 patients reported by Melamed [12] , Pearson 
Adenocarcinoma
Unlike squamous cell carcinoma in which a combination of X-rays and sputum cytology are useful for the early detection of the lesion, adenocarcinomas are found in the periphery of the lung where they are not likely to shed malignant cells into the sputum, and therefore are detected on X-ray. Mass X-ray screening has not been very sucessful. The Philadelphia Lung Cancer Detection Program, using small films, was unable to demonstrate an improvement in survival in their patients detected by screen as opposed to those who presented with lung cancer [17] . Newer screening methods have been tried and have at least yielded peripheral adenocarcinomas which are at a lower stage for treatment.
RESULTS OF SCREENING STUDIES
Baker and his associates [18] reported the surgical experience in treating the patients found in a screening program for over 10,000 men-half of whom had chest X-rays and half of whom had chest X-rays and sputum cytologic studies. Thirtynine patients underwent resection for cure, an overall resectability rate of 55 percent. Five All three of these studies have been undertaken in an effort to determine the feasibility of screening to detect cancer of the lung at a curable stage. None of these studies has yet been able to demonstrate a difference in the overall survival rate between screened and control groups. In part, this may be due to the fact that the followup period is not sufficiently long at this time. Only time will tell whether a true reduction in mortality consistent with that predicted by the detection of low-stage disease cases can be achieved or whether the disease has only been detected earlier in a course which is unaltered.
Another major concern regarding screening for lung cancer is the economic feasibility of such a program. Chest X-rays and sputum cytologies are relatively expensive procedures when compared with a Pap smear or a stool analysis for occult blood. Obviously, there is a real need to identify a high-risk group of patients who should be subjected to this costly screening process and to lower its cost. Major efforts have been made in both areas, but there is nothing which appears ready for clinical application at this time.
In summary, much has been learned about the natural history of lung cancer. All this information suggests that the therapeutic modalities which are currently available can be very effective when used at an early stage of the disease. They also show the ineffectiveness of these techniques when used in late-stage disease. Unfortunately, over 80 percent of lung cancers present at an advanced stage. In the absence of an effective preventive program, screening to detect early-stage lung cancer appears to offer the only hope for improved survival from this disease. The very real needs at this time are for refinement in the identification of a truly highrisk group, and for more economical ways of screening.
